Virksomhedsform
Anpartsselskab
Etableret
2004
Størrelse
Mellemstore
Ansatte
98
Omsætning
- DKK
Bruttofortj.
103 MDKK
Primært resultat (EBIT)
28 MDKK
Årets resultat
24 MDKK
Egenkapital
54 MDKK
annonce

Flere nøgletal og analyser?

Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!

Rang Årets resultat

Rang i branche
1/271
"Top 10%"
Rang i Danmark
6.011/360.024
"Top 10%"

Direktion top 3

Bestyrelse top 3

Jesper Ahlmann Funding Andersen 7Bestyrelsesformand

Legale ejere top 3

Tegningsregler

Selskabet tegnes af én direktør, ét bestyrelsesmedlem eller af den samlede bestyrelse.

Stamoplysninger baseret på CVR

NavnFertio Aps
BinavneEuropean Egg Bank Aps, European Sperm Bank Aps, Nordic Cryobank Aps, Nordic Cryobank Group Aps, Nordisk Cryobank Aps, The European Sperm Bank Aps, Fertio Aps, Nordisk Cryoban K Aps Vis mere
CVR27506372
AdresseStruenseegade 9, 2, 2200 København N
BrancheDrift af sundhedsvæsen i øvrigt i.a.n. [869900]
Etableret12-01-2004 (21 år)
Første regnskabsperiode12-01-2004 til 31-12-2004
VirksomhedsformAnpartsselskab
Antal ansatte143 (årsværk:107)
ReklamebeskyttelseJa
RevisorDeloitte Statsautoriseret Revisionspartnerselskab siden 26-10-2019
Regnskabsperiode01-01 til 31-12
Selskabskapital270.000 DKK
250.000 DKK (23-02-2007 - 25-03-2019)
375.000 DKK (07-04-2004 - 22-02-2007)
250.000 DKK (12-01-2004 - 06-04-2004)
Vedtægter seneste23-04-2025

Medlem af brancherne

Formål

Selskabets formål er at drive virksomhed ved healthcare virksomhed og dermed forbundet produktion og anden aktivitet.

Regnskab

 202420232022
Valuta/enhed000' DKK000' DKK000' DKK
Omsætning
-
-
-
-
-
-
Bruttofortjeneste
102.724
-32%
149.984
+41%
106.303
-4%
Årets resultat
24.466
-59%
60.218
+70%
35.385
-33%
Egenkapital
53.913
-34%
81.446
-11%
91.229
+8%
Balance
171.882
-6%
182.968
+19%
153.923
+17%

Ledelsesberetning sammendrag

Beskrivelse af virksomhedens væsentligste aktiviteter
Primary activitiesFertio ApS’s primary activities are within the fertility industry and related production
.​The company in 2025 changed its primary name to Fertio Aps, retaining its former name: European Sperm Bank as a secondary name. Both names will be used going forward.
​The purpose of the introduction of the name Fertio was to enable future expansion of scope of services beyond sperm banking.
Beskrivelse af usikkerhed ved indregning eller måling
Uncertainty relating to recognition and measurementMeasurement of certain assets and liabilities is based on accounting estimates made by Management. These
estimates are made in accordance with the accounting policies and based on Management’s assumptions and
experience. The estimates made are considered realistic and prudent.
The areas subject to assumptions and estimates that are considered material to the financial statements are
intangible assets, investments in group enterprises, inventories and other provisions.
Specifically inventories are subject to assumptions and estimates as the number of sellable straws depends on many factors such as donor characteristics and regulatory restrictions for provision of donor sperm.
Inventories are measured at cost including direct and indirect production costs. Indirect production costs are assessed on an ongoing basis to ensure relevant and reliable measurement.
Changes in assumptions, estimates and assessment of indirect production costs may have an impact on the
gross margin and the overall valuation of inventory.
Apart from this, there are no particular uncertainties relating to recognition and measurement.
Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen
Unusual circumstances affecting recognition and measurementNo significant unusual circumstances affecting recognition and measurement have occurred.
Beskrivelse af udviklingen i virksomhedens aktiviteter og økonomiske forhold
Development in activities and financesManagement considers the result for the financial year to be in line with the expectations for the core business. Operating profit decreased to 28 mDKK in 2024, impacted by a non-recurring inventory provision, and closure of the laboratory facility in London. Excluding these effects, the company maintained a solid operational performance.
Omtale af betydningsfulde hændelser, som er indtruffet efter regnskabsårets afslutning
Events after the balance sheet dateNo events have occurred after the balance sheet date to this date, which would influence the evaluation of this
annual report.
Beskrivelse af virksomhedens forventede udvikling
OutlookFor 2025 Management expects operating profit between 80-90 mDKK and net result between 52-62 mDKK.
Generalforsamlingsdato: 26-06-2025

Kort